Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland.
Cancer. 2022 Jun 15;128(12):2269-2280. doi: 10.1002/cncr.34190. Epub 2022 Mar 25.
B7 homolog 3 (B7-H3) is an immunomodulatory molecule that is highly expressed in prostate cancer (PCa) and belongs to the B7 superfamily, which includes PD-L1. Immunotherapies (antibodies, antibody-drug conjugates, and chimeric antigen receptor T cells) targeting B7-H3 are currently in clinical trials; therefore, elucidating the molecular and immune microenvironment correlates of B7-H3 expression may help to guide trial design and interpretation. The authors tested the interconnected hypotheses that B7-H3 expression is associated with genetic racial ancestry, immune cell composition, and androgen receptor signaling in PCa.
An automated, clinical-grade immunohistochemistry assay was developed by to digitally quantify B7-H3 protein expression across 2 racially diverse cohorts of primary PCa (1 with previously reported transcriptomic data) and pretreatment and posttreatment PCa tissues from a trial of intensive neoadjuvant hormonal therapy.
B7-H3 protein expression was significantly lower in self-identified Black patients and was inversely correlated with the percentage African ancestry. This association with race was independent of the significant association of B7-H3 protein expression with ERG/ETS and PTEN status. B7-H3 messenger RNA expression, but not B7-H3 protein expression, was significantly correlated with regulatory (FOXP3-positive) T-cell density. Finally, androgen receptor activity scores were significantly correlated with B7-H3 messenger RNA expression, and neoadjuvant intensive hormonal therapy was associated with a significant decrease in B7-H3 protein expression.
The current data underscore the importance of studying racially and molecularly diverse PCa cohorts in the immunotherapy era. This study is among the first to use genetic ancestry markers to add to the emerging evidence that PCa in men of African ancestry may have a distinct biology associated with B7-H3 expression.
B7-H3 is an immunomodulatory molecule that is highly expressed in prostate cancer and is under investigation in clinical trials. The authors determined that B7-H3 protein expression is inversely correlated with an individual's proportion of African ancestry. The results demonstrate that B7-H3 messenger RNA expression is correlated with the density of tumor T-regulatory cells. Finally, in the first paired analysis of B7-H3 protein expression before and after neoadjuvant intensive hormone therapy, the authors determined that hormone therapy is associated with a decrease in B7-H3 protein levels, suggesting that androgen signaling may positively regulate B7-H3 expression. These results may help to guide the design of future clinical trials and to develop biomarkers of response in such trials.
B7 同源物 3(B7-H3)是一种免疫调节分子,在前列腺癌(PCa)中高度表达,属于 B7 超家族,其中包括 PD-L1。针对 B7-H3 的免疫疗法(抗体、抗体药物偶联物和嵌合抗原受体 T 细胞)目前正在临床试验中;因此,阐明 B7-H3 表达的分子和免疫微环境相关性可能有助于指导试验设计和解释。作者检验了 B7-H3 表达与 PCa 中遗传种族起源、免疫细胞组成和雄激素受体信号之间相互关联的假设。
作者开发了一种自动化的临床级免疫组织化学检测方法,用于数字化定量检测来自两个种族多样化的原发性 PCa 队列(其中一个队列具有先前报道的转录组数据)以及强化新辅助激素治疗试验中的预处理和治疗后 PCa 组织中 B7-H3 蛋白的表达。
自我认定为黑人的患者中 B7-H3 蛋白表达明显较低,并且与非洲血统的百分比呈负相关。这种与种族的关联独立于 B7-H3 蛋白表达与 ERG/ETS 和 PTEN 状态的显著关联。B7-H3 信使 RNA 表达,但不是 B7-H3 蛋白表达,与调节性(FOXP3 阳性)T 细胞密度显著相关。最后,雄激素受体活性评分与 B7-H3 信使 RNA 表达显著相关,强化新辅助激素治疗与 B7-H3 蛋白表达的显著降低有关。
目前的数据强调了在免疫治疗时代研究具有种族和分子多样性的 PCa 队列的重要性。本研究是首次使用遗传祖先标记物来补充新兴证据,即非洲裔男性的 PCa 可能具有与 B7-H3 表达相关的独特生物学特性。
B7-H3 是一种免疫调节分子,在前列腺癌中高度表达,正在临床试验中进行研究。作者确定 B7-H3 蛋白表达与个体的非洲裔比例呈负相关。结果表明,B7-H3 信使 RNA 表达与肿瘤 T 调节细胞的密度相关。最后,在新辅助强化激素治疗前后首次对 B7-H3 蛋白表达进行配对分析时,作者确定激素治疗与 B7-H3 蛋白水平的降低有关,表明雄激素信号可能正向调节 B7-H3 表达。这些结果可能有助于指导未来临床试验的设计,并为此类试验中反应的生物标志物的开发提供信息。